- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Celularity and Arthrex Enter into Exclusive Commercial Supply and Distribution Agreement
Celularity Inc., a clinical-stage biotechnology company developing cell therapies and biomaterial products derived from the postpartum human placenta to treat cancer, infectious and degenerative diseases, and Arthrex, Inc., have announced the companies have entered into an exclusive partnership to distribute and commercialize Celularity’s biomaterial products for orthopedic surgery and sports medicine. Under the terms of the agreement, Celularity will provide Arthrex with exclusive commercial distribution rights for orthopedic surgery and sports medicine and will continue to be responsible for product manufacturing and supply.
For more information, click here.
The State of Mining Data Insights in the Life Sciences Industry – 2024
April 30th 2024A Frost & Sullivan industry-wide survey reveals which insights most pharmaceutical companies have mastered and which are still painful or impossible to extract and details the complexity of the process, the confidence companies have in their findings, and more. Hear Web Sun, President and Co-founder of Komodo Health, share what's driving these challenges and how you can overcome them.
